Search for a command to run...
Nanostructured lipid carriers (NLCs) are widely investigated as versatile drug delivery systems. In this study, we aimed to design, synthesize, and characterize a novel fluorescently labeled NLC platform incorporating a rhodamine B–oleic acid conjugate (Rd-OA) as a proof-of-concept model for future therapeutic applications. NLCs were prepared using Precirol® ATO 5, oleic acid and Rd-OA, and Tween® 20 (T20) or Tween® 80 (T80). The resulting nanoparticles exhibited sizes of 350–500 nm, narrow polydispersity indices (<0.2), and highly negative zeta potentials (∼–30 mV), confirming stable colloidal properties. Rd-OA was efficiently integrated (100% incorporation efficiency) with different concentrations. Molecular dynamics simulations provided atomic-level structural insights, revealing surfactant-dependent differences in component organization consistent with experimental data. NLCs were stable over a period of three months. In vitro assays in keratinocytes cells demonstrated a concentration-dependent cytotoxicity effect influenced by Rd-OA content, while fluorescence microscopy confirmed efficient cellular internalization of the NLCs. Collectively, these findings support the developed fluorescent NLC system as a stable, reproducible, and traceable platform suitable for future adaptation in drug delivery and imaging applications.” • Developed a novel nanostructured lipid carrier (NLC) system covalently linked to a fluorescent dye for combined drug delivery and bioimaging. • Demonstrated enhanced nanoparticle stability, supported by in silico modeling predictions and experimental validation. • Achieved reliable real-time tracking and precise localization through covalent dye integration, minimizing dye leakage and false signals. • Validated the biocompatibility of the NLC system, ensuring safety for biomedical applications. • Presented a versatile, multifunctional nanocarrier platform with strong potential for clinical translation in theranostics and precision medicine.
Published in: Journal of Drug Delivery Science and Technology
Volume 114, pp. 107612-107612